Vistagen’s Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen shares plunge after its Phase 3 fasedienol trial for social anxiety failed to meet the primary endpoint, despite favorable safety data.
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday.
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday’s Mid-Day Session
Gainers
SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice's Federal Bureau of Investigation.
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
After the markets closed on Tuesday, VistaGen Therapeutics Inc (NASDAQ:VTGN) reported a Q3 FY23 net loss of $(9.8) million or $(0.05) per…
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell
• BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In Q1 2023
In the race to create faster-acting, safer antidepressants, Vistagen (NASDAQ:VTGN) is starting the year strong as it gets ready to launch a Phase 1 Trial of its novel pherine nasal spray for Major Depressive
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday’s Mid-Day Session
Gainers
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Cardio Diagnostics Hldgs (NASDAQ:CDIO) shares moved upwards by 41.7% to $1.46 during Friday’s after-market session. The company’s…
Vistagen Receives FDA “Study May Proceed” Letter Under Its Investigational New Drug Application For PH10 To Treat Major Depressive Disorder
Vistagen, (NASDAQ:VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today
Earnings Outlook For VistaGen Therapeutics
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement.
Analysts estimate that VistaGen Therapeutics will report an earnings per share (EPS) of $-0.07.